1. Home
  2. VTGN

VTGN

VistaGen Therapeutics Inc.

Logo VistaGen Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.

Founded: 1998 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 143.4M IPO Year: N/A
Target Price: $19.00 AVG Volume (30 days): 278.8K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.43 EPS Growth: N/A
52 Week Low/High: $1.62 - $24.71 Next Earning Date: 02-13-2024
Revenue: $1,042,300 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -80.89%

Share on Social Networks: